⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of AusperBio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
AusperBio
↗San Francisco, USA
AusperBio is a clinical-stage biopharmaceutical company focused on developing oligonucleotide therapeutics, specifically targeting a functional cure for chronic hepatitis B (CHB). The company utilizes its proprietary Med-Oligo™ antisense oligonucleotide (ASO) platform, which incorporates targeted delivery technologies to enhance therapeutic precision and reduce side effects.
Beyond its primary focus on viral infections like HBV, AusperBio is expanding its pipeline to address metabolic conditions, genetic disorders, and immune diseases. The company operates as a private entity with international operations, including significant research and development activities in China and the United States.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oligonucleotide Therapeutics / Infectious Disease
SIZE & FINANCIALS
Employees:51-200
Ownership:private
Status:operating
FUNDING
Stage:Series B2
Total Raised:$223M
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Antisense Oligonucleotide (ASO)
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Ausper Biopharma Co., Ltd.
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Dr. Guofeng Cheng - Co-Founder & CEO
Dr. Chris Yang - Co-Founder & CSO
LINKS
Website:ausperbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AusperBio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.